Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone

Fig. 3

Showing stable AST/ALT trend since diagnosis of malignant melanoma before peaking 2 weeks after starting nivolumab maintenance therapy. AST peaked at 811 and ALT peaked at 1565 U/L. Transaminitis improved after initiation of prednisone 1 mg/kg and stopping nivolumab. Patient experienced another episode of grade 2 transaminitis and his prednisone was increased back to 20 mg per day before tapering again. Patient had another episode of grade 1 transaminitis resulting in small adjustment of prednisone. [G = Grade]

Back to article page